When: Credible Montgomery strategic vision on October 1

Then: Re-evaluate toward Hold/Overweight on credible CEO transition and strategic clarity

REDUCE to 30-40% of benchmark with widened stops at $219, hedged with January 2027 180-strike puts

• Worst-case multiple compression to 15-16x on $9.30 EPS yields $140-$150 (vs aggressive's $175-$180 base case)
• Goodwill of $47.4B against equity of $52.6B leaves minimal equity cushion; worst-case scenario including impairment and integration failure targets $150-$160
• Recommended stop at $215 is only $6.50 (0.93x ATR of $7.02) above entry—vulnerable to single volatile up-day; should be widened to $219 (1.5x ATR)
• Position sizing should be 30-40% of benchmark (vs aggressive's 50-70%), with January 2027 180-strike puts hedging catastrophic downside rather than March 2027 190-strike puts
• Enter short at $208.5 only if stock reaches that level; if it stalls at $204 and rolls over, prefer that entry with tighter stop at $211-$212
• October 1 new CEO announcement creates elevated volatility regardless of direction due to unquantifiable credibility; close position pre-event if unprofitable
• Macro base case (8% recession odds) is under-informed due to absence of confirmed CPI, PCE, or unemployment data in the brief
• Volatility signature shows 11% single-day crash on 4x volume followed by 14% rebound in three weeks—pattern consistent with 2022-2023 downtrend characterized by sharp bounces that shake out shorts

→ vs aggressive: Directionally correct to trim but insufficiently conservative on sizing (50-70% vs recommended 30-40%), stop placement ($215 vs recommended $219), and tail-risk hedging depth

→ vs neutral: Over-anchored to benign base case assuming macro stability and successful integration as central scenario; ignores worst-case $140-$150 and $150-$160 scenarios

Trim to 60-70% of benchmark with selective hedging; avoid full exit or heavy defensive posture

• Forward EPS 9.30 vs TTM 5.62 suggests 65% earnings rebound, contradicting bear case that dismisses recovery as "fake"
• Technical setup: MACD turned bullish (histogram plus 0.44), RSI at 60.96 with room to run, 200 SMA reclaim after 11 sessions below
• Conservative analyst error: lower strike puts have higher deltas, not lower; "cheaper on delta" framing is analytically wrong
• Conservative stop at 219 is 10 dollars above Bollinger resistance at 210.64, making the trade unprofitable by design
• Impairment risk is 2027-2028 issue, not 2026, as Abbott Molecular deal just closed; bear case overweights near-term impairment
• Peer cohort strength (TMO raised guidance, ABT +13% sales, JNJ beat and raised) contradicts sector-collapse thesis underlying bear case
• Beta 0.80 and $5 billion annual free cash flow support sustained buybacks through integration difficulties
• Recession odds at 8%, status-quo D-House outcome at 88% probability; "risk-on, slow-cut, soft-landing" regime structurally supportive
• World affairs report described backdrop as "structurally supportive of high-quality diagnostics compounders"
• Proposed trim entry on rallies toward 207–209; wider stop at 213 (1.2x ATR above upper Bollinger band)
• Reduce position to 50% if stock breaks 200 SMA on volume in next two weeks
• Reassess and potentially add back post-CEO transition on October 1 depending on strategic narrative

→ vs aggressive: Aggressive analyst double-counts bear case by discounting earnings upside while pricing in downside with full conviction; cannot argue recovery is fake AND compress multiple for weak fundamentals

→ vs aggressive: Aggressive analyst treats 200 SMA reclaim as fade opportunity while dismissing broader momentum setup (MACD, RSI, 50 SMA rising) — cherry-picking bearish signals

→ vs aggressive: Aggressive analyst treats absence of multiple expansion tailwind as headwind; stable rates in soft-landing regime is constructive, not neutral

→ vs aggressive: Entry at 208.50 doesn't make sense when stock is at 204.76; trim should happen at current levels, not waiting for dead-cat bounce to 208.50

→ vs aggressive: Sizing to 50-70% is too heavy given integration risk, but full exit is overcorrected given 60-70% range better balances caution with strategic position preservation

→ vs conservative: Conservative analyst incorrectly states lower strike puts are "cheaper on delta" — lower strike puts have higher deltas, making them more expensive not less

→ vs conservative: 180 strike puts hedge tail scenario (stock breaks to 150-160) requiring sector-wide derating to 15x, which needs recession (8% odds) plus biotech funding pullback plus peer compression plus DHR-specific impairment — probability much lower than implied

→ vs conservative: Position sizing at 30-40% of benchmark is underweight given actual tail probability; opportunity cost is meaningful with $5B FCF and early technical regime change signals

→ vs conservative: Neither analyst addresses cost of hedges in "Volmageddon" zero-cuts environment; should size hedge to cover 30-40% of position, not 50%

→ vs conservative: Both analysts treat October 1 as binary event; better framework is underweight going in with option to add back on confirmation of strategic vision